Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Products under Development by Stage of Development | 8 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Products under Development by Therapy Area | 9 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Products under Development by Indication | 10 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Products under Development by Companies | 13 | 2 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Products under Development by Universities/Institutes | 15 | 2 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Companies Involved in Therapeutics Development | 24 | 9 |
| Amicus Therapeutics, Inc. | 24 | 1 |
| Audentes Therapeutics, Inc. | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 26 | 1 |
| Etubics Corporation | 27 | 1 |
| Genzyme Corporation | 28 | 1 |
| greenovation Biotech GmbH | 29 | 1 |
| Oxyrane Belgium NV | 30 | 1 |
| Pharming Group N.V. | 31 | 1 |
| Sarepta Therapeutics, Inc. | 32 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Drug Profiles | 33 | 15 |
| Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease Drug Profile | 33 | 1 |
| AT-982 Drug Profile | 34 | 1 |
| ATB-200 + miglustat Drug Profile | 35 | 2 |
| Gene Therapy 1 to Activate Acid Alpha-Glucosidase for Pompe Disease Drug Profile | 37 | 1 |
| Gene Therapy 2 to Activate Acid Alpha-Glucosidase for Pompe Disease Drug Profile | 38 | 1 |
| Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease Drug Profile | 39 | 1 |
| GZ-402666 Drug Profile | 40 | 2 |
| MOSS-GAA Drug Profile | 42 | 1 |
| OXY-2810 Drug Profile | 43 | 1 |
| Recombinant Alpha Glucosidase Replacement for Pompe Disease Drug Profile | 44 | 1 |
| reveglucosidase alfa Drug Profile | 45 | 2 |
| VAL-1221 Drug Profile | 47 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Dormant Projects | 48 | 1 |
| Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Featured News &Press Releases | 49 | 13 |
| Mar 03, 2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease | 49 | 1 |
| Mar 01, 2016: Amicus Therapeutics Highlights Preclinical Pompe Data at WORLDSymposium 2016 | 50 | 1 |
| Feb 10, 2016: Amicus Therapeutics Announces Oral and Poster Presentations on Chaperone AT2221 at 12th Annual WORLDSymposium 2016 | 51 | 1 |
| Jan 11, 2016: BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference | 51 | 1 |
| Jan 11, 2016: Amicus Therapeutics Provides Update On Novel ERT for Pompe Disease (ATB200 + Chaperone) | 52 | 1 |
| Dec 22, 2015: Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease | 53 | 1 |
| Sep 30, 2015: BioMarin to Present Research Results on Duchenne Muscular Dystrophy and Pompe Disease Programs at the 20th International Congress of the World Muscle Society | 54 | 1 |
| Sep 03, 2015: Valerion Therapeutics Announces Positive Results Of Non-Clinical Research Study at SSIEM Annual Symposium | 55 | 1 |
| May 11, 2015: Audentes Therapeutics To Present New Data On AT-002 at American Society of Gene and Cell Therapy Annual Meeting | 56 | 1 |
| Feb 10, 2015: Amicus Therapeutics Presents Preclinical Data on Next-Generation Pompe ERT at WORLD Symposium 2015 | 56 | 1 |
| May 27, 2014: BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease | 57 | 1 |
| Mar 19, 2013: BioMarin Announces Results From Phase I/II Trial Of BMN-701 For Treatment Of Pompe Disease, Plans To Initiate Phase II/III Trial | 58 | 1 |
| Jan 19, 2011: BioMarin Initiates Phase I/II Trial For BMN 701 For Treatment Of Pompe Disease | 59 | 1 |
| Aug 30, 2010: BioMarin Receives FDA Orphan Drug Designation For BMN-701 For Treatment Of Pompe Disease | 60 | 1 |
| Aug 18, 2010: BioMarin Pharmaceutical Acquires ZyStor Therapeutics, Furthers Development Of BMN-701 (ZC-701) For Pompe Disease | 60 | 2 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |